Mirum Pharmaceuticals, Inc. Foreign Currency Transaction Gain Loss Realized After Tax
Mirum Pharmaceuticals, Inc. (MIRM) reported Foreign Currency Transaction Gain Loss Realized After Tax of $700.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossRealizedAfterTax · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain loss realized after tax for the quarter ending 2026-06-30 was $700.00K.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain loss realized after tax for the quarter ending 2026-03-31 was $0.00.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain loss realized after tax for the quarter ending 2025-12-31 was $0.00.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain loss realized after tax for the quarter ending 2025-09-30 was -$200.00K.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain loss realized after tax for fiscal 2025 was -$1.00M.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain loss realized after tax for fiscal 2024 was $0.00.
- Mirum Pharmaceuticals, Inc. foreign currency transaction gain loss realized after tax for fiscal 2023 was $0.00.
| Period end | Foreign Currency Transaction Gain Loss Realized After Tax 3 month | Foreign Currency Transaction Gain Loss Realized After Tax 6 month | Foreign Currency Transaction Gain Loss Realized After Tax 9 month | Foreign Currency Transaction Gain Loss Realized After Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $700.00K 10-Q · filed 2026-08-05 | $800.00K 10-Q · filed 2026-08-05 | $700.00K derived: sum of 3 quarters · filed 2026-08-05 | $500.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | -$200.00K derived: sum of 3 quarters · filed 2026-05-06 | -$500.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$200.00K derived: sum of 2 quarters · filed 2026-02-25 | -$500.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.00M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$200.00K 10-Q · filed 2025-11-04 | -$500.00K derived: sum of 2 quarters · filed 2026-08-05 | -$1.00M 10-Q · filed 2025-11-04 | -$500.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$300.00K 10-Q · filed 2026-08-05 | -$700.00K 10-Q · filed 2026-08-05 | -$300.00K derived: sum of 3 quarters · filed 2026-08-05 | -$300.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | $0.00 derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |